Tempest Therapeutics, Inc. (TPST)
Chart Events
Performance Outlook
| Previous Close | 13.90 |
| Open | 13.72 |
| Bid | 13.55 x 900 |
| Ask | 14.01 x 1000 |
| Day's Range | 13.51 - 14.10 |
| 52 Week Range | 10.39 - 41.55 |
| Volume | 7,811 |
| Avg. Volume | 117,633 |
| Market Cap | 90.896M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.04 |
| Earnings Date | Nov 08, 2021 - Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.00 |
Fair Value
Related Research
- Tempest Therapeutics, Inc.Daily – Vickers Top Insider Picks for 10/20/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic MoatyesterdayArgus Research
- GlobeNewswire
Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of a presentation on TPST-1495, a selective antagonist of both EP2 and EP4 prostaglandin receptors, at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021 at the Walter
- GlobeNewswire
Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
Trial to Evaluate TPST-1120/atezolizumab/bevacizumab triplet compared to atezolizumab/bevacizumab aloneSOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the first patient has been dosed in the global randomized Phase 1b/2 clinical study evaluating TPST-1120, Tempest’s small molecule
- GlobeNewswire
Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
• Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that it has entered into an exclusive license with the University of California at Berkeley for intellectual property covering a drug target that was discovered in the laboratory of R
